Introduction
============

Nasopharyngeal carcinoma (NPC) arises from the nasopharyngeal epithelium and has an extremely unbalanced geographical distribution with high incidence in some areas of southern China, northern Africa and Alaska [@B1]. Because of the anatomic constraints and its high radiosensitivity, radiotherapy is the primary and only curative treatment modality for non-metastatic NPC [@B2]. Although prognosis of patients with NPC has improved, loco-reginal recurrence (LRR) of disease is still a critical problem just second to distant metastasis. Unfortunately, it is not clear what the optimal interval and modalities for detecting LRR without symptoms are. Despite the various surveillance strategies to monitor recurrence for NPC after IMRT, however, it is not clear whether early detection of a recurrence would improve prognosis. Therefore, a prognostic tool enabling accurately predicting LRR are required for NPC.

Substantive research has indicated a variety of clinicopathological covariates such as T/N category, plasma Epstein-Barr virus (EBV)-DNA copy number, the primary gross tumor volume and pretreatment LDH are associated with LRR [@B12]-[@B16]. However, none of them is sufficiently accurate in routine practice to identify patients at risk of recurrence. Therefore, it may be beneficial to integrate a variety of comprehensive clinicopathological information, including anatomic factors, host factors and pathological factors, in a manner that enables accurate prediction of LRR. Such tools may help to optimize individualized treatment and follow-up strategies to further increase loco-regional control in NPC.

Nomogram is a reliable, pragmatic predictive tool that provides a simple graphical representation of statistical predictive models to quantify individual risk by incorporating a variety of risk factors for a clinical event [@B22], [@B23]. Nomograms have been developed for many types of cancer and been proven to provide more precise predictions than the traditional TNM staging system and univariate prognostic factors [@B22], [@B23], [@B24]. To date, nomograms have not yet been devised to predict LR or RR for NPC receiving radical IMRT. In this study, we undertook a large-scale study, with the aim of generating reliable, pragmatic nomograms for LR-free and RR-free rate using comprehensive clinical and pathological variables.

Materials and Methods
=====================

Patient characteristics
-----------------------

A database with a total of 1811 consecutive newly biopsy-proven, non-metastatic NPC treated with IMRT at our center between October 2009 and February 2012 was prospective maintained. The medical data including electronic medical records and imaging data of each patient was firstly retrospectively collected, and then routinely prospectively followed up on the basis of internal schedule. Moreover, telephone follow-up was performed for who did not appear to follow-up at our center or when we think it was necessary for other reasons. Routine staging workup including a complete medical history, physical examination, hematology and biochemistry profiles, nasopharyngeal fiberoptic endoscopy, nasopharyngeal and neck MRI, chest radiography, abdominal sonography and whole body bone scan using 99mTc-methyldiphosphonate single photon emission computed tomography (SPECT) were performed for all patients. All patients were restaged according to the 7th edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) staging system [@B34]. This study was approved by the institutional ethics committee and all the methods were carried out in accordance with The Code of Ethics of the World Medical Association. Informed consent was obtained from every patient prior to therapy.

Treatment
---------

The nasopharyngeal and neck tumor target volumes of all patients were treated using radical IMRT in the process of the entire treatment course. Target volumes were delineated slice-by-slice on the treatment planning CT scans using an individualized delineation protocol in accordance with International Commission on Radiation Units and Measurements reports 62 and 83. Prescribed doses were 66-72Gy at 2.12- 2.43 Gy/fraction to planning target volume (PTV) of primary gross tumour volume (GTVp), 64-70 Gy to PTV of GTV of involved lymph nodes (GTVnd), 60-63 Gy to PTV of high-risk clinical target volume (CTV1), and 54-56 Gy to PTV of low-risk clinical target volume (CTV2). All targets were treated simultaneously using the simultaneous integrated boost technique; other details of the techniques used at our center have previously been reported [@B25].

According to institutional guidelines, we recommended RT alone for stage I, concurrent chemoradiotherapy (CCRT) for stage II, and CCRT ± neoadjuvant/adjuvant chemotherapy for stage III to IVA-B. Of the 1811 patients, 256 (14.1%) received IMRT alone; 1356 (74.9%) received concurrent chemotherapy, of whom 675 (37.3%) received neoadjuvant chemotherapy, 42 (2.3%) received adjuvant chemotherapy; and 199 (11.0%) received neoadjuvant chemotherapy +/- adjuvant chemotherapy. Neoadjuvant/adjuvant chemotherapy consisted of cisplatin with 5-fluorouracil, cisplatin with docetaxel, or cisplatin with 5-fluorouracil and docetaxel were administered at intervals of 3 weeks for two to four cycles. Concurrent chemotherapy was the single drug cisplatin administered every three weeks or weekly during the treatment course of radiotherapy.

Patient follow-up
-----------------

Each patient was assessed for treatment response and toxicity every week during treatment, every 3 months during the first 2 years after radiotherapy and every 6 months thereafter (or until death). The main endpoints of interest were local recurrence (LR) and regional recurrence (RR), defined as tumor residual or relapse at least 3 months after initial IMRT. All LR were confirmed via fiber-optic endoscopy and biopsy or MRI scan (or both) of nasopharynx and skull base showing progressive bone erosion and soft tissue swelling. All RR were diagnosed by clinical examination of neck and by fine-needle aspiration, or MRI of neck (or both). Interval times for LR and RR were calculated and defined as the duration between commencement of radiotherapy and first detection of any evidence of LR and RR.

Designing of predictive nomograms
---------------------------------

Univariate analysis was performed using Cox proportional hazard regression models to determine the hazard ratios for LR and RR. The complexity of the models was controlled using the Akaike information criteria. Nomograms for the probabilities of LR and RR at 36 and 60 months were generated. Values for each of the model covariates were mapped to points on a scale axis ranging from 0-100. The total points summed for each model covariate were mapped to the probability of LR or RR associated with the specific combination of covariate values [@B22], [@B23]. The predictive accuracy of the nomograms was evaluated by assessing discrimination and calibration, and measures of predictive accuracy were validated using a 1000 bootstrap resampling method. Discrimination between patients with or without LR and RR was assessed using the concordance index (c-index), a variable equivalent to the area under the receiver operating characteristic curve (AUC). A c-index of 0.5 indicates the random chance of correctly predicting the outcome; 1.0 indicates perfect distinction between predicted and actual outcomes. Biases of predictive performance were first estimated using bootstrap samples, then corrected with apparent measures to produce bias-corrected values to avoid overfitting [@B24]. Calibration was performed using a calibration curve incorporating the model-predicted and actual probabilities.

Finally, we determined the cutoff values of nomogram generated scores with which patients were evenly stratified into three or four risk groups: low, middle, high risk and very high. The predictive value of the classifications were estimated by means of the hazard ratio (HR) and its 95% confidence interval (95% CI) between the groups thereby generated and LR and RR.

Statistical analysis
--------------------

Time-to-event data were described using Kaplan-Meier curves and the differences were compared with the log-rank test. Receiver operating characteristic (ROC) curve analyses were applied to determine optimal cut-off points, which were defined by maximizing the conditional Youden score, for continuous variables with respect to loco-regional recurrence. The multivariate Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Univariate and Multivariate Cox proportional hazard regression models were conducted using SPSS software, version 22.0 (SPSS, Chicago, IL, USA). Establishment and verification of nomograms were implemented using the open source software R-version 3.2.5 with rms packages (Design, Vienna, Austria). All tests were two-sided; *p*-values \< 0.05 were considered statistically significant.

Results
=======

Loco-regional recurrence and survival
-------------------------------------

With a median follow up of 49.50 months (ranging, 1.3-76.4 months), 90 patients developed LR and 75 patients developed regional recurrence RR, respectively. The 5- year LR-free rate and RR-free rate were 94.30% and 95.41% respectively, with median durations of 22.99 and 20.20 months to LR and RR respectively.

The detailed clinicopathological characteristics and treatment factors for the 1811 patients are listed in Table [1](#T1){ref-type="table"}. The male: female ratio was 3:1 (1351 males, 460 females); patients ranged in age from 14 to 78 years-old (median, 45 years). Histological examination revealed 94.4% of patients had undifferentiated NPC, and 5.6% had differentiated NPC. The T category distribution was T1: 326 (18%); T2: 282 (15.6%); T3: 864 (47.7%); and T4: 339 (18.7%). Overall, 308 (17%) patients staged N0; 1062 (58.6%) staged N1; 276 (15.2%) staged N2; 165 (9.1%) staged N3.

Predictive nomogram for LR
--------------------------

The results of univariate and multivariate analyses for LR are summarized in Table [2](#T2){ref-type="table"}. Twenty-three factors were significantly associated with LR in univariate analysis (*P* \< 0.05). However, only six factors remained significant in multivariate analyses. The influential predictors identified in the Cox proportional hazards regression models in addition to volume of GTVp were included to generate the nomogram for LR. As shown in Figure [1](#F1){ref-type="fig"}A, the factors finally included in the model for LR were: age, the neutrophil/leukocyte ratio (NWR), pathological type, primary gross tumor volume, maxillary sinus invasion, ethmoidal sinus invasion and lacerated foramen invasion.

The c-index of the nomogram for LR was 0.76 (95% CI; 0.71 to 0.81), which was significantly better than that of the TNM classification (0.61; 95% CI, 0.55 to 0.67; *P*\< 0.001). The predicted probabilities at 3- and 5- years obtained from the bootstrap correction and actual probabilities of LR are illustrated in the calibration plot (Figure [2](#F2){ref-type="fig"}A). Both plots showed good agreement between predicted and observed LR, with the calibration curves close to the 45 degree broken line indicating the nomogram was calibrated accurately.

Predictive nomogram for RR
--------------------------

The univariate and multivariate analyses for RR are summarized in Table [3](#T3){ref-type="table"}. Univariate analyses indicated that C-reactive protein (CRP), plasma EBV-DNA copy number, N category and volume of GTVnd were significant for RR. CRP had no significant value in multivariate analyses, while NWR become significant in the multivariate analysis when combined with other factors and adjusted using the stepwise regression method. NWR, EBV-DNA copy number, cervical lymph node volume and N category were finally included to generate the nomogram for RR (Figure [1](#F1){ref-type="fig"}B).

The c-index of the predictive model for RR was 0.74 (95% CI; 0.68 to 0.80), which was significantly higher than that of TNM classification (0.64; 95% CI, 0.58 to 0.70; *P* \< 0.001). The calibration curves for the probability of RR at 3- and 5-years corresponded to the 45 degree broken line (Figure [2](#F2){ref-type="fig"}B), indicating the nomogram provided perfect prediction of RR.

Stratifying risk for individual patients using nomograms
--------------------------------------------------------

All patients were stratified into different risk groups (4 groups for LR; 3 groups for RR) according to the total points summed for each model covariate. The cutoff values of the nomogram-generated scores for stratification of LR were 142, 221, and 304; and the scores for stratification of RR were 93 and 219. These stratifications could effectively discriminate LR and RR for the proposed risk groups (Figure [3](#F3){ref-type="fig"}). The log-rank test reveals that the survival functions factored by prognostic categories are significantly different (*P* \< 0.0001). It is worth noting that high-middle-risk patients had increased risk of loco-regional failure, with HR of 2.07 (95% CI, 1.71-2.50) for LR, and 3.11 (95% CI, 1.98-4.89) for RR.

Discussion
==========

In this study, we generated nomograms using widely-assessed clinicopathological information to predict the probability of LR-free and RR-free survival for patients with NPC after radical radiation therapy. Both models were well generated: the nomograms for LR and RR had c-indexes of 0.76 and 0.74, respectively, indicating the discriminative performance of the models was close to perfect. The calibration curves for the models intuitively suggested good agreement between the predictions and observations, supporting the goodness-of-fit of the nomogram predictions to the data. To our knowledge, these are the first nomograms developed to predict the probability of LR-free and RR-free rate for patients with NPC after radical IMRT.

The TNM staging system, in which tumor size, tumor invasion and the extent of lymph node involvement are stratified, is the most commonly used tool for clinicians to predict the prognosis of patients with NPC. However, with the widespread application of IMRT, the loco-regional control rate for NPC has greatly improved as IMRT offers excellent target volume coverage and sparing for the normal tissues adjacent to the targets [@B17], which may reduce the predictive value of T category for LR and RR to a certain extent [@B20]. Furthermore, varieties of clinicopathological covariates - in addition to TNM stage - are associated with LR and RR [@B12]-[@B16]. On the other hand, the nomograms for LR-free and RR-free rate generated in this study include all relevant covariates and enable accurate prediction of LR and RR. The c-indexes of the nomograms were significantly higher than those of the TNM classification, indicating the significantly better predictive capacity of the nomograms.

The risk factors identified for LR were age, NWR, pathological type, primary gross tumor volume, maxillary sinus invasion, ethmoidal sinus invasion and lacerated foramen invasion. NWR is one of the major human inflammatory indicators and serve as key effectors in the first-line of host defense against infectious microorganisms. Substantial evidence indicates inflammation is a critical component that promotes tumor progression [@B30], [@B31]. High NWR is also an independent prognostic factor in NPC [@B31]. Neutrophils in the peripheral circulation and tumor microenvironment can produce proangiogenic factors, such as vascular endothelial growth factor, that stimulate tumor development [@B31]. Some cytokines involved in cancer-related inflammation and myeloid growth factors produced by cancer cells can induce neutrophilia [@B31].

The primary gross tumor volume has also been proven to be relevant to LR [@B4], [@B13], [@B14]. Many patients with a large primary gross tumor volume experience tumor hypoxia, which is strongly associated with disease progression and resistance to therapy [@B28], [@B29]. Besides, a larger primary gross tumor volume often reflects a heavier tumor cell burden, thus may further contribute to radioresistance. Furthermore, a larger primary gross tumor volume indicates the tumor lies closer adjacent to the organs at risk (OARs), and dose reductions may be necessary to protect critical normal tissues. Therefore, all of these adverse factors may contribute to increased risk of LR.

Certain sites invasion including maxillary sinus, ethmoidal sinus and lacerated foramen were found to be adverse factors for local recurrence in our series. These structures have close relation with the surrounding anatomic structures, and can be involved by tumor through mucosa crawl or direct invasion. IMRT can create a more conformal distribution around the targets than two-dimensional (2-D) radiation therapy, and the high dose region is defined by the precise three-dimensional (3-D) sectional anatomy. Thus, result in smaller CTV with IMRT. Therefore, it has higher chance to local recurrence for diseases with these structures involved.

The variables identified for the nomogram for RR-free rate were NWR, EBV-DNA copy number, cervical lymph node volume and N category. A recent Medline review by Wang *et al.* [@B32] stressed the important role of tumor-associated neutrophils (TANs) in the development and progression of cancer. TANs can promote tumor metastasis (including regional and distant metastasis) via various mechanisms. For example, matrix metalloproteinase 9 (MMP-9) is a type IV collagen that can be secreted by tumor cells and TANs in the tumor microenvironment. MMP-9 is involved in a wide range of physiological and pathological process in the body, such as wound healing, angiogenesis and inflammatory responses. Abnormal expression of MMP-9 is closely associated with metastasis in many types of cancer [@B32]. However, while it is not yet known whether MMP-9 produced by tumor cells promotes tumor angiogenesis and metastasis, MMP-9 produced by inflammatory cells clearly promotes angiogenesis and tumor progression [@B32].

The relevance of plasma EBV-DNA copy number to RR has been reported in several studies [@B12]. Lin *et al.*[@B12] demonstrated the presence of EBNA-1 DNA in peripheral blood cells was predictive of a high risk of metastasis, and the circulating EBV DNA copy number correlates with tumor stage and the likelihood of recurrence [@B12]. They defined a pretreatment cut-off value of 1500 copies per milliliter, and concluded that plasma EBV DNA represents a useful molecular marker for prediction of recurrence in NPC [@B12].

The cervical lymph node volume was significant for RR in univariate and multivariate analysis. Patients with larger cervical lymph nodes have higher incidence of cervical nodal necrosis and should receive a higher radiation dose. Besides, although all patients are immobilized during radiation using a thermoplastic head and shoulder mask, the neck is the least fixed region of the irradiation area. Therefore, large baseline shifts may occur during the long-time treatment course, which may result in under-dosing of the cervical lymph node.

Moreover, the risk group stratifications generated using the nomogram-generated scores could effectively discriminate for LR and RR. Aggressive therapy to patients with high risk of recurrence according to our nomograms may be proposed. Neoadjuvant chemotherapy before radiotherapy could reduce tumor volume, and improve gross tumor volume coverage and tumor control. Adaptive radiotherapy (ART) adjusts the treatment plan to systematic changes observed during RT, and restores the target dose in the case of anatomic changes, which may also improve tumor control for the high-risk group.

The nomograms established in this study possess a number of limitations. The nomograms were not subjected to external validation, as we did not acquire a validation cohort. However, internal validation was applied using bootstrap resampling to avoid over-fitting of the data. Future validation suing external prospective data of larger cohorts are warranted to confirm these results.

Conclusion
==========

In conclusion, the nomograms generated in this study will allow clinicians to make accurate predictions of LR and RR for NPC treated with radical IMRT. Additional studies are required to determine whether it can be applied to other patient groups.
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###### 

Patient characteristics and treatment factors (*n* = 1811)

  Characteristic                        No. (*n*= 1811)   \%
  ------------------------------------- ----------------- ------
  *Patient and tumor characteristics*                     
  Sex                                                     
  Male                                  1351              74.6
  Female                                460               25.4
  Age (years)                                             
  Median                                45                
  Range                                 14-78             
  Smoking                                                 
  Yes                                   659               63.6
  No                                    1152              36.4
  WHO histologic type                                     
  Differentiated                        101               5.6
  Undifferentiated                      1710              94.4
  T category                                              
  T1                                    326               18
  T2                                    282               15.6
  T3                                    864               47.7
  T4                                    339               18.7
  N category                                              
  N0                                    308               17
  N1                                    1062              58.6
  N2                                    276               15.2
  N3                                    165               9.1
  Stage                                                   
  I                                     99                5.5
  II                                    381               21
  III                                   856               47.3
  IV                                    475               26.2
  *Treatment factors*                                     
  IMRT prescribed dose (Gy/Fr)          66-72/28-33       
  Chemotherapy (no/yes)                                   
  None                                  256               14.1
  CCRT + /- ACT                         681               37.6
  CCRT + NCT                            675               37.3
  NCT + /- ACT                          199               11.0

Abbreviation: CCRT: concurrent chemoradiotherapy; NCT: neoadjuvant chemotherapy; ACT: adjuvant chemotherapy.

###### 

Predictive factors for LR in univariate and multivariate analysis

                                                        Univariate analysis (*P*)   Multivariate analysis               
  ----------------------------------------------------- --------------------------- ----------------------- ----------- ---------
  Sex (Male/Female)                                     0.087                                                           NS
  Age (\>46 /≤46 years)                                 0.081                       1.54                    1.00-2.35   0.049
  Smoking (No/Yes)                                      0.901                                                           NS
  WBC /× 10^9^ (\>7.72/≤7.72)                           0.014                                                           NS
  Neu /× 10^9^ (\>4.53/≤4.53)                           0.005                                                           NS
  Lym/× 10^9^ (\>1.50/≤1.50)                            0.064                                                           NS
  NWR (\>0.64/≤0.64)                                    \<0.001                     1.86                    1.20-2.87   0.005
  NLR (\>2.36/≤2.36)                                    \<0.001                                                         NS
  LDH /U/L (\>187 /≤187)                                0.052                                                           NS
  CRP /mg/L (\>2.36/≤2.36)                              0.076                                                           NS
  EBV-DNA /copies/ml (\> 2830/≤ 2830)                   0.014                                                           NS
  Pathological type (differentiated/undifferentiated)   0.015                       0.50                    0.26-0.96   0.038
  Nasopharynx                                           0.024                                                           NS
  Nasal cavity                                          0.096                                                           NS
  Levator veli palatine muscle                          0.034                                                           NS
  Tensor veli palatini muscle                           0.045                                                           NS
  Vertebral anterior muscle                             0.019                                                           NS
  Parapharyngeal space                                  0.016                                                           NS
  Infratemporal fossa                                   0.599                                                           NS
  Pterygoid process                                     \<0.001                                                         NS
  Base of sphenoid bone                                 0.107                                                           NS
  Maxillary sinus                                       \<0.001                     3.33                    1.42-7.81   0.006
  Sphenoid sinus                                        \<0.001                                                         NS
  Ethmoidal sinus                                       \<0.001                     2.98                    1.39-6.40   0.005
  Foramen Lacerated                                     \<0.001                     2.40                    1.48-3.88   \<0.001
  Foramen Ovale                                         0.001                                                           NS
  Cavernous sinus                                       \<0.001                                                         NS
  Medial Pterygoid                                      0.014                                                           NS
  External Pterygoid                                    0.226                                                           NS
  Clivus                                                \<0.001                                                         NS
  Petrous Apex                                          0.001                                                           NS
  Great Wing of Sphenoid Bone                           \<0.001                                                         NS
  Primary gross tumor volume /cc                                                                                        
  ≤21.33                                                Ref.                        Ref.                                
  21.33-75.50                                           0.058                                                           NS
  \>75.50                                               \<0.001                                                         NS
  Cumulative dose to GTVp /Gy (\>68/≤68)                0.278                                                           NS
  Chemotherapy                                                                                                          
  None                                                  Ref.                        Ref.                                
  Neoadjuvant ± Concurrent                              0.105                                                           NS
  Concurrent                                            0.108                                                           NS

Abbreviation: 95% CI: 95% confidence interval; HR: hazard ratio; Ref.: reference value; WBC: white blood cells; Neu: neutrophils; Lym: lymphocyte; NWR: neutrophil/leukocyte ratio; NLR: neutrophil/lymphocyte ratio; LDH: lactate dehydrogenase; CRP: C-reactive protein; GTVp: primary nasopharyngeal gross tumor volume; NS: not significant.

###### 

Predictive factors for RR in univariate and multivariate analysis

                                                Univariate analysis (*P*)   Multivariate analysis                 
  --------------------------------------------- --------------------------- ----------------------- ------------- -------
  Sex (Male/Female)                             0.199                                                             NS
  Age (\>64 /≤64 years)                         0.371                                                             NS
  Smoking (No/Yes)                              0.815                                                             NS
  WBC /× 10^9^ (\>7.09/≤7.09)                   0.272                                                             NS
  Neu /× 10^9^ (\>4.15/≤4.15)                   0.391                                                             NS
  Lym/× 10^9^ (\>0.95/≤0.95)                    0.311                                                             NS
  NWR (\>0.54/≤0.54)                            0.138                       2.761                   1.106-3.023   0.030
  NLR (\>1.87/≤1.87)                            0.130                                                             NS
  LDH /U/L (\>195 /≤195)                        0.172                                                             NS
  CRP /mg/L (\>9.77/≤9.77)                      0.029                                                             NS
  EBV-DNA /copies/ml (\>2635/≤2635)             \<0.001                     2.113                   1.305-3.421   0.028
  Histology (differentiated/undifferentiated)   0.192                                                             NS
  N category                                                                                                      
  N0                                            Ref.                        Ref.                                  
  N1                                            0.010                                                             NS
  N2                                            0.002                                                             NS
  N3                                            0.001                                                             NS
  cervical lymph node volume /cc (\>7.1/≤7.1)   \<0.001                     2.434                   1.259-4.708   0.008
  Cumulative dose to GTVnd /Gy (\>64/≤64)       0.476                                                             NS
  Chemotherapy                                                                                                    
  None                                          Ref.                                                              NS
  Neoadjuvant ± Concurrent                      0.982                                                             NS
  Concurrent                                    0.052                                                             NS

Abbreviations: 95% CI: 95% confidence interval; HR: hazard ratio; Ref.: reference value; WBC: white blood cells; Neu: neutrophils; NWR: neutrophil/leukocyte ratio; NLR: neutrophil/lymphocyte ratio; LDH: lactate dehydrogenase; CRP: C-reactive protein; GTVnd: tumor volume for involved cervical lymph nodes; NS: not significant.
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